Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health services and systems news

Show

From To
Misunderstanding of questions regarding anal sex in microbicide HIV prevention trial

There was widespread misunderstanding and misinterpretation of questions about anal sex being asked of participants in the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial,

Published
10 November 2014
By
Lesley Odendal
Addiction services in England: in need of an intervention

With change comes both opportunity and chaos: an assertion nowhere more true than with England's addiction services. Over the past 5 years, government initiatives to increase cost-effectiveness have opened up bidding for local services to third-party providers. With increased competition, the thinking went, bloated NHS trusts would sharpen their edges and the quality of care would be improved.

Published
10 November 2014
From
The Lancet Psychiatry
HIV generics in the U.S.: Sooner or later?

Why do we continue to spend billions of dollars for brand-name drugs that are available in cheaper generic forms in the developing world -- billions that end up as profits for pharmaceutical industry?

Published
10 November 2014
From
The Body
Study Finds Retention Problems Among South African Patients Receiving HIV Treatment

Fewer than half of patients who tested HIV-positive at a Johannesburg, South Africa clinic returned to complete eligibility testing for antiretroviral therapy (ART), suggesting that “strategies to reduce attrition from all stages of care are urgently needed,” a new study led by a BU researcher finds.

Published
07 November 2014
From
Boston University press release
Innovation in fixed-dose combos: HIV/AIDS therapeutics edition

FDC drug development is evolving rapidly as the industry gains experience in manufacturing them and ushering them through the review process. The laws have changed towards a more favorable marketing climate. And finally, it is clear that FDCs are more than a way to improve adherence—though that will always be a prominent consideration. FDCs can shift the standard of care towards a more tolerable, patient-friendly, value-oriented approach to treatment, and in the final analysis, that approach to development bodes well for companies, payers, and most importantly, patients.

Published
07 November 2014
From
BioPharma Dive
D-day for The Pill for HIV

The media coverage of the unexpectedly early success of two trials of pre-exposure prophylaxis - PrEP - has generally been positive, sometimes overly so. But I haven't seen anything that actually explains why the results of the PROUD and IPERGAY studies are so important, or why they represent a gear-change in the accelerating race towards the end of HIV.

Published
05 November 2014
From
Huffington Post
Problems with test and treat in Thailand

The Thai government has announced that the national policy is test and treat. There are several problems with this.

Published
05 November 2014
From
HIV Information for Myanmar (blog)
UK has 'signed a death warrant' for South Africans with HIV-Aids

One of the world’s leading Aids activists has accused Britain of “signing a death warrant” for South Africans in need of treatment after withdrawing aid from the Treatment Action Campaign, which now faces ruin.

Published
05 November 2014
From
The Guardian
Bristol-Myers Plan to Widen Access to its Hep C Drug is Criticized

“Unfortunately, history seems to be repeating itself with BMS, who hasn’t learned from the company’s poor track record responding to the HIV epidemic,” says Rohit Malpani of Doctors Without Borders.

Published
05 November 2014
From
Wall Street Journal
NIH Trial Tests Very Early Anti-HIV Therapy in HIV-Infected Newborns

​A new clinical trial is exploring whether giving anti-HIV therapy soon after birth to infants who became infected with HIV in the womb leads to remission of the virus, enabling the children eventually to stop treatment for an extended time period. The trial aims to build on the case of the 'Mississippi Baby'.

Published
05 November 2014
From
National Institute of Allergy and Infectious Diseases (NIAID) press release

Filter by country